Document 0269
 DOCN  M95A0269
 TI    Human immunodeficiency virus-1 gp120 and gp160 envelope proteins
       modulate mesangial cell gelatinolytic activity.
 DT    9510
 AU    Singhal PC; Sagar S; Chandra D; Garg P; Department of Medicine, Long
       Island Jewish Medical Center, New; Hyde Park, New York 11040, USA.
 SO    Am J Pathol. 1995 Jul;147(1):25-32. Unique Identifier : AIDSLINE
       MED/95328620
 AB    Patients with human immunodeficiency virus (HIV) infection often develop
       glomerular lesions (mesangial expansion and sclerosis). Modulation of
       matrix degradation may be important in the expansion of the mesangium.
       We studied the effect of HIV sera and HIV-1 envelope glycoproteins on
       gelatinolytic activity of human mesangial cells. HIV serum-treated cells
       showed lower (P < 0.01) gelatinolytic activity when compared with cells
       treated with control serum (control serum, 4.3 +/- 0.1 versus HIV serum,
       3.3 +/- 0.1 micrograms gelatin degraded/mg protein). Mesangial cells
       incubated with HIV-1 gp120 protein also showed decreased (P < 0.01)
       gelatinolytic activity (control, 4.6 +/- 0.2 versus HIV-1 gp120 protein,
       1.7 +/- 0.2 micrograms gelatin degraded/mg protein). HIV-1 gp160 protein
       also inhibited (P < 0.05) mesangial cell gelatinolytic activity as
       judged by a biotin-avidin assay as well as by a 3H gelatin degradation
       assay. In contrast, gp alpha-1 acid, a nonviral glycoprotein, did not
       modulate mesangial cell gelatinolytic activity. These results suggest
       that the serum contents of HIV patients decrease gelatinolytic activity
       of mesangial cells. This effect of HIV sera seems to be mediated through
       HIV-1 gp proteins.
 DE    Acquired Immunodeficiency Syndrome/BLOOD  Cells, Cultured
       Cytokines/BLOOD  Dose-Response Relationship, Drug  Extracellular
       Matrix/METABOLISM  Gelatin/*METABOLISM  Gelatinases/*METABOLISM  Gene
       Products, env/*PHARMACOLOGY  Glomerular Mesangium/CYTOLOGY/DRUG
       EFFECTS/*METABOLISM  Human  HIV Antibodies/ANALYSIS  HIV Envelope
       Protein gp120/*PHARMACOLOGY  HIV Infections/BLOOD  *HIV-1  Protein
       Precursors/*PHARMACOLOGY  Serum Albumin/ANALYSIS  Support, U.S. Gov't,
       P.H.S.  Viral Proteins/PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).